ACADIA Pharmaceuticals Inc. (ACAD): Price and Financial Metrics
GET POWR RATINGS... FREE!
ACAD POWR Grades
- ACAD scores best on the Value dimension, with a Value rank ahead of 81.77% of US stocks.
- ACAD's strongest trending metric is Value; it's been moving up over the last 31 weeks.
- ACAD's current lowest rank is in the Momentum metric (where it is better than 5.04% of US stocks).
ACAD Stock Summary
- For ACAD, its debt to operating expenses ratio is greater than that reported by only 11.35% of US equities we're observing.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 1.22 for Acadia Pharmaceuticals Inc; that's greater than it is for merely 13.37% of US stocks.
- With a year-over-year growth in debt of 894.76%, Acadia Pharmaceuticals Inc's debt growth rate surpasses 98.38% of about US stocks.
- Stocks that are quantitatively similar to ACAD, based on their financial statements, market capitalization, and price volatility, are NTLA, SWIR, ZYME, SILK, and SGMO.
- ACAD's SEC filings can be seen here. And to visit Acadia Pharmaceuticals Inc's official web site, go to www.acadia-pharm.com.
ACAD Stock Price Chart Interactive Chart >
ACAD Price/Volume Stats
|Current price||$25.93||52-week high||$58.72|
|Prev. close||$26.27||52-week low||$19.20|
|Day high||$26.72||Avg. volume||1,998,186|
|50-day MA||$22.07||Dividend yield||N/A|
|200-day MA||$39.50||Market Cap||4.15B|
ACADIA Pharmaceuticals Inc. (ACAD) Company Bio
Acadia Pharmaceuticals Inc is a biotechnology company which develops and commercializes biopharmaceutical products to address central nervous system disorders. The firm aims to discover small molecule drugs to address Parkinson's, Alzheimer's and schizophrenia. The company was founded in 1993 by Mark Brann, PhD., a professor at the University of Vermont, under the name Receptor Technologies. By 1997, the company established its headquarters in San Diego, California and changed its name to Acadia Pharmaceuticals Inc and currently employs over 400 people. Since 2015, Stephen R. Davis serves as Acadia’s Chief Executive Officer and member of the board of directors. Competition for Acadia includes Otsuka Pharmaceutical Co., Ltd., H. Lundbeck A/S, and off-label branded and generic antipsychotics.
ACAD Latest News Stream
|Loading, please wait...|
ACAD Latest Social Stream
View Full ACAD Social Stream
Latest ACAD News From Around the Web
Below are the latest news stories about Acadia Pharmaceuticals Inc that investors may wish to consider to help them evaluate ACAD as an investment opportunity.
NEW YORK, NY / ACCESSWIRE / June 15, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court.
Acadia Pharmaceuticals, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm
Investors with losses are encouraged to contact the firm before June 18, 2021; click here to submit trade information LOS ANGELES, June 15, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) investors that acquired shares between June 15, 2020 - Apr. 4, 2021. Investors have until June 18, 2021 to seek an active role in this litigation. Investors are encouraged to contact attorney Lesl
ACAD 3-DAY DEADLINE ALERT: Hagens Berman Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact the Firm Now
San Francisco, California--(Newsfile Corp. - June 15, 2021) - Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. Class Period: June 15, 2020 - Apr. 4, 2021Lead Plaintiff Deadline: June 18, 2021Visit: www.hbsslaw.com/investor-fraud/ACADContact An Attorney Now: [email protected] 844-916-0895Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) Securities Fraud Action:The complaint alleges that Defendants misrepresented facts concerning A
3-Day Deadline Alert: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 15, 2021 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ACADIA Pharmaceuticals Inc. ('Acadia' or 'the Company') (NASDAQ:ACAD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.
NEW YORK, NY / ACCESSWIRE / June 15, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment.
ACAD Price Returns
Continue Researching ACADHere are a few links from around the web to help you further your research on Acadia Pharmaceuticals Inc's stock as an investment opportunity:
Acadia Pharmaceuticals Inc (ACAD) Stock Price | Nasdaq
Acadia Pharmaceuticals Inc (ACAD) Stock Quote, History and News - Yahoo Finance
Acadia Pharmaceuticals Inc (ACAD) Stock Price and Basic Information | MarketWatch